Back to Market返回行情

PACB Pacific Biosciences of California, Inc.

USHealthcare
$1.56-3.11%ClosedMarket Cap: $484.5M

As of 2026-07-10 16:00

Why PACB matters now

Pacific Biosciences of California, Inc. (PACB) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.56 with -3.11% on the session and $484.5M in market capitalization; recent performance reads 1-month +21.74% and YTD -25.13%.

The latest financial table shown here is Q1 2026, with revenue of $37.2M, net income of $-8.3M, and EPS of $-0.03. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -26.7%.

The latest indexable market news headline is "Here's Why You Should Add PacBio Stock to Your Portfolio Now" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Hold with a median target of $1.00; recent insider activity includes ORDONEZ KATHY filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

180.96

P/S

2.72

EV/EBITDA

-10.15

DCF Value

$-10.51

FCF Yield

-26.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

37.1%

Operating Margin

-101.7%

Net Margin

-80.3%

ROE

-488.4%

ROA

-16.4%

ROIC

-22.7%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$37.2M$-8.3M$-0.03
Q4 2025$44.6M$-40.4M$-0.13
FY 2025$160.0M$-546.4M$-1.82
Q3 2025$38.4M$-38.0M$-0.13

Analyst Ratings

Consensus

Hold

Target (Consensus)

$1.00

Target (Median)

$1.00

Target Range

$1.00 - $1.00

Strong Buy: 0Buy: 4Hold: 2Sell: 0Strong Sell: 1
BarclaysUnderweight
2026-05-11
BarclaysUnderweight
2026-03-06
BarclaysEqual Weight
2025-12-15
Piper SandlerNeutral
2025-11-11
Stephens & Co.Overweight
2025-11-10

Trading Activity

Insider Trades

ORDONEZ KATHYdirector
Sell2026-06-04
MILLIGAN JOHN Fdirector
Sell2026-06-04
Ericson William W.director
Sell2026-06-04
LIVINGSTON RANDALL Sdirector
Sell2026-06-04
Valantine Hannahdirector
Sell2026-06-04

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

2.32

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.